These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 30411802)

  • 1. Assessing the time dependence of prognostic values of cytology and human papillomavirus testing in cervical cancer screening.
    Isidean SD; Wang Y; Mayrand MH; Ratnam S; Coutlée F; Franco EL; Abrahamowicz M;
    Int J Cancer; 2019 May; 144(10):2408-2418. PubMed ID: 30411802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical efficacy of primary human papillomavirus (HPV) screening with partial genotyping for HPV-16 and HPV-18 subtypes in women from 25 years old.
    Ang JX; Lee WY; Tay SK
    Ann Acad Med Singap; 2023 May; 52(5):259-267. PubMed ID: 38904523
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 16/18 genotyping in triage of persistent human papillomavirus infections with negative cytology in the English cervical screening pilot.
    Rebolj M; Brentnall AR; Mathews C; Denton K; Holbrook M; Levine T; Sargent A; Smith J; Tidy J; Tyler X; Kitchener H;
    Br J Cancer; 2019 Sep; 121(6):455-463. PubMed ID: 31409912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Performance and Diagnostic Accuracy of a Urine-Based Human Papillomavirus Assay in a Referral Population.
    Cuzick J; Cadman L; Ahmad AS; Ho L; Terry G; Kleeman M; Lyons D; Austin J; Stoler MH; Vibat CRT; Dockter J; Robbins D; Billings PR; Erlander MG
    Cancer Epidemiol Biomarkers Prev; 2017 Jul; 26(7):1053-1059. PubMed ID: 28223432
    [No Abstract]   [Full Text] [Related]  

  • 5. Immediate risk of cervical intraepithelial neoplasia and diagnostic value of colposcopy among cytology-negative women with oncogenic HPV: a retrospective study.
    Dai W; Wang T; Chen L; Qiu Z; Chen P; Chen D
    BMC Womens Health; 2024 Jul; 24(1):419. PubMed ID: 39049047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of high-performance human papillomavirus testing to improve cervical cancer screening in China: a prospective population-based multicentre cohort study.
    Yin J; Zhang S; Li Z; Li Y; Wang H; Zhang X; Pan Q; Chen W; Luo X; Sun X; Zhao F; Qiao Y
    Clin Microbiol Infect; 2024 Sep; 30(9):1190-1196. PubMed ID: 38599463
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Minor Cytological Abnormalities and up to 7-Year Risk for Subsequent High-Grade Lesions by HPV Type.
    Persson M; Elfström KM; Olsson SE; Dillner J; Andersson S
    PLoS One; 2015; 10(6):e0127444. PubMed ID: 26083247
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of cervical high-grade squamous intraepithelial lesions and assessing diagnostic performance of colposcopy among women with oncogenic HPV.
    Li X; Xiang F; Zhao Y; Li Q; Gu Q; Zhang X; Chen Z; Zhang M; Wang J; Liu R; Kang X; Wu R
    BMC Womens Health; 2023 Aug; 23(1):411. PubMed ID: 37542333
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Burden and genotype distribution of high-risk Human Papillomavirus infection and cervical cytology abnormalities at selected obstetrics and gynecology clinics of Addis Ababa, Ethiopia.
    Ali KE; Mohammed IA; Difabachew MN; Demeke DS; Haile T; Ten Hove RJ; Kumssa TH; Woldu ZL; Haile EL; Tullu KD
    BMC Cancer; 2019 Aug; 19(1):768. PubMed ID: 31382907
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Screening outcome of HPV-vaccinated women: Data from the Danish Trial23 cohort study.
    Nonboe MH; Napolitano GM; Kann C; Andersen B; Bennetsen MH; Christiansen S; Frandsen AP; Rygaard C; Salmani R; Schroll JB; Lynge E
    PLoS One; 2024; 19(6):e0306044. PubMed ID: 38917143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of a validated methylation triage signature for human papillomavirus positive women in the HPV FOCAL cervical cancer screening trial.
    Cook DA; Krajden M; Brentnall AR; Gondara L; Chan T; Law JH; Smith LW; van Niekerk DJ; Ogilvie GS; Coldman AJ; Warman R; Reuter C; Cuzick J; Lorincz AT
    Int J Cancer; 2019 May; 144(10):2587-2595. PubMed ID: 30412281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice.
    Katki HA; Kinney WK; Fetterman B; Lorey T; Poitras NE; Cheung L; Demuth F; Schiffman M; Wacholder S; Castle PE
    Lancet Oncol; 2011 Jul; 12(7):663-72. PubMed ID: 21684207
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evidence of Decreased Long-term Risk of Cervical Precancer after Negative Primary HPV Screens Compared with Negative Cytology Screens in a Longitudinal Cohort Study.
    Gottschlich A; Hong Q; Gondara L; Alam MS; Cook DA; Martin RE; Lee M; Melnikow J; Peacock S; Proctor L; Stuart G; Franco EL; Krajden M; Smith LW; Ogilvie GS
    Cancer Epidemiol Biomarkers Prev; 2024 Jul; 33(7):904-911. PubMed ID: 38773687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Performance of Different Follow-Up Strategies and Genotype-Based Recurrence Risk After Treatment of Cervical High-Grade Squamous Intraepithelial Lesion.
    Graça J; Preti M; Pollano B; Vieira-Baptista P
    J Low Genit Tract Dis; 2024 Apr; 28(2):131-136. PubMed ID: 38465957
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of high-grade precancerous lesions and invasive cancers in high-risk HPV-positive women with normal cervix or CIN 1 at baseline-A population-based cohort study.
    Mittal S; Basu P; Muwonge R; Banerjee D; Ghosh I; Sengupta MM; Das P; Dey P; Mandal R; Panda C; Biswas J; Sankaranarayanan R
    Int J Cancer; 2017 Apr; 140(8):1850-1859. PubMed ID: 28108997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of colposcopy after the addition of human papillomavirus testing to the Turkish cervical cancer screening program.
    Gunes AC; Ozgul N; Turkyılmaz M; Kara F; Unlu F; Ayhan A; Gultekin M
    Cancer Med; 2023 Dec; 12(24):21751-21760. PubMed ID: 37994572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extended Human Papillomavirus Genotyping to Predict Progression to High-Grade Cervical Precancer: A Prospective Cohort Study in the Southeastern United States.
    Bukowski A; Hoyo C; Hudgens MG; Brewster WR; Valea F; Bentley RC; Vidal AC; Maguire RL; Schmitt JW; Murphy SK; North KE; Smith JS
    Cancer Epidemiol Biomarkers Prev; 2022 Aug; 31(8):1564-1571. PubMed ID: 35654413
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of using human papillomavirus 16/18 genotype triage in cervical cancer screening.
    Vijayaraghavan A; Efrusy MB; Goodman KA; Santas CC; Huh WK
    Gynecol Oncol; 2010 Nov; 119(2):237-42. PubMed ID: 20713299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of HPV vaccination on cervical screening performance: a population-based cohort study.
    Lei J; Ploner A; Lehtinen M; Sparén P; Dillner J; Elfström KM
    Br J Cancer; 2020 Jul; 123(1):155-160. PubMed ID: 32362659
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Attendance at early recall and colposcopy in routine cervical screening with human papillomavirus testing.
    Green LI; Mathews CS; Waller J; Kitchener H; Rebolj M;
    Int J Cancer; 2021 Apr; 148(8):1850-1857. PubMed ID: 33070318
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.